On the next day, both treatment cohorts were further subdivided into two groups: for one group treatment was continued without further modification, while the other group additionally received IL-2 subcutaneously at the tumor site on day 1, 3, 5, and 7 post therapy initiation to assess the cytokine's impact to therapeutic efficacy. Here, IL2 is linked to neoplasm.